Literature DB >> 28750129

Pemetrexed in Nonsquamous Non-Small-Cell Lung Cancer: The Billion Dollar Subgroup Analysis.

Bishal Gyawali1, Vinay Prasad2,3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 28750129     DOI： 10.1001/jamaoncol.2017.1944

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  3 in total

1.  Missing Conflict of Interest Disclosure.

Authors: 
Journal:  JAMA Oncol       Date:  2018-10-01       Impact factor: 31.777

2.  Comparative Effectiveness of Carboplatin/Pemetrexed With Versus Without Bevacizumab for Advanced Nonsquamous Non-Small Cell Lung Cancer.

Authors:  Stephen J Bagley; Suzanna Talento; Nandita Mitra; Neal J Meropol; Roger B Cohen; Corey J Langer; Anil Vachani
Journal:  J Natl Compr Canc Netw       Date:  2019-05-01       Impact factor: 11.908

3.  Hospitalization and Survival of Medicare Patients Treated With Carboplatin Plus Paclitaxel or Pemetrexed for Metastatic, Nonsquamous, Non-Small Cell Lung Cancer.

Authors:  Gabriel A Brooks; Andrea M Austin; Hajime Uno; Konstantin H Dragnev; Anna N A Tosteson; Deborah Schrag
Journal:  JAMA Netw Open       Date:  2018-10-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.